RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on February 4 and set a ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 1,002 put options on the company.

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

TriLink BioTechnologies & Aldveron ink non-exclusive license and supply agreement for CleanCap mRNA capping technology: San Diego, US Thursday, February 6, 2025, 15:00 Hrs [IST] T ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a leading provider of critical products to enable the development of drug therapies, diagnostics, and novel vaccines, has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Board declared a quarterly dividend of $0.125 per share, payable on April 3, 2025 to shareholders of record on March 12, 2025.